Tom Hayes, Libor ‘Ringleader,' Wins U.K. Appeal to Clear His Name
The U.K. Supreme Court on Wednesday quashed the landmark 2015 conviction, which saw Hayes spend more than five years in prison before he was released in 2021.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Apple, Google Under Fire: UK Regulators Launch Bold Crackdown on Browser Monopoly
July 23 Britain's Competition and Markets Authority plans to designate Apple (NASDAQ:AAPL) and Google (NASDAQ:GOOGL) with strategic market status over their mobile ecosystems. The CMA's inquiry found markets relating to mobile internet browsers were not working well for consumers or businesses. Apple's Safari and Google's Chrome together dominate browsing on iPhones and Android handsets. A strategic market status designation would allow the CMA to impose interventions requiring firms to follow specific behaviours to protect fair competition. CMA chief Sarah Cardell said the measures would help UK app developers remain at the forefront of innovation and ensure users receive a world?class experience. The regulator highlighted opportunities for more innovation and choice. A final decision is due by Oct. 22, with roadmaps published for potential next steps. Google's senior director for competition, Oliver Bethell, called the move disappointing and unwarranted and warned against rules that could impede growth in the UK. Apple said it was concerned the proposed steps might undermine the privacy and security protections users expect. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
4 minutes ago
- Yahoo
ImmunityBio's (IBRX) ANKTIVA Gets Approved by UK's Medicines and Healthcare Regulatory Agency
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the . On July 8, ImmunityBio, Inc. (NASDAQ:IBRX) announced that the UK's Medicines and Healthcare products Regulatory Agency has approved ANKTIVA with Bacillus Calmette-Guérin for treating certain bladder cancer patients. This is significant as it marks the first approval for the company outside of the United States of America. Moreover, the drug is a first-in-class IL-15 agonist, which works by activating and multiplying immune cells, specifically NK cells and T cells that help the body fight cancer. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. In addition, clinical studies have shown strong results as some patients maintained a complete response for over 47 months at the last review. ImmunityBio, Inc. (NASDAQ:IBRX) is a biopharmaceutical company that develops therapies and vaccines that boost the immune system to fight cancer and infectious diseases. While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
TechCrunch
6 minutes ago
- TechCrunch
UK targets Apple and Google's mobile platforms for regulation
In Brief The U.K.'s Competition and Markets Authority (CMA) announced on Wednesday a proposal that would give Apple and Google's mobile platforms 'strategic market status' — a designation that allows the regulator to create rules that could change how their app stores operate and how their mobile software works. The move is designed to create a more open, competitive environment for the app economy and user choice. However, Apple and Google have pushed back at the proposals, with Apple saying changes would compromise user security and privacy. A final decision on the matter will arrive in October, after the two companies present their cases. If the proposal goes through, it would give the CMA the ability to address issues like the commission rates on in-app purchases, the app review process, app rankings, restrictions on developer access to certain technology, and default settings that could reduce competition, among other things. Tim Sweeney, CEO of Epic Games, which has been involved in antitrust lawsuits against the tech giants, expressed his disappointment in the proposed roadmap, as it doesn't allow for competing mobile app stores like the Epic Games Store.
